See more : Banyan Gold Corp. (BYN.V) Income Statement Analysis – Financial Results
Complete financial analysis of Tenaya Therapeutics, Inc. (TNYA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tenaya Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Group Five Pipe Saudi Ltd. (9523.SR) Income Statement Analysis – Financial Results
- Splunk Inc. (0R09.L) Income Statement Analysis – Financial Results
- Union Auction Public Company Limited (AUCT.BK) Income Statement Analysis – Financial Results
- Georg Fischer AG (GF.SW) Income Statement Analysis – Financial Results
- Tianqi Lithium Corporation (9696.HK) Income Statement Analysis – Financial Results
Tenaya Therapeutics, Inc. (TNYA)
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| Gross Profit | -8.69M | -8.71M | -4.03M | -2.48M | -1.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.04M | 94.54M | 54.39M | 31.10M | 23.15M |
| General & Administrative | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Other Expenses | 0.00 | 2.00K | -23.00K | 430.00K | 1.03M |
| Operating Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Cost & Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Interest Income | 7.06M | 1.95M | 108.00K | 87.00K | 453.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| EBITDA | -122.51M | -114.95M | -68.70M | -36.43M | -25.72M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -131.19M | -125.62M | -72.81M | -38.91M | -27.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.11M | 1.96M | 85.00K | 517.00K | 1.48M |
| Income Before Tax | -124.08M | -123.67M | -72.72M | -38.40M | -26.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.96K | -3.07M | -87.00K | -453.00K |
| Net Income | -124.08M | -123.66M | -69.65M | -38.31M | -25.78M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EPS Diluted | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| Weighted Avg Shares Out | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
| Weighted Avg Shares Out (Dil) | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress
Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences
Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Tenaya Therapeutics to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports